Dissertations / Theses: 'Radiopharmaka'

1

Jäckel, Thilo. "Synthese und Charakterisierung peptidgebundener Rheniumoxo-Komplexe als Radiopharmaka /." München : Hieronymus, 1999. http://www.gbv.de/dms/bs/toc/318510324.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rief, Christoph [Verfasser], Maja [Akademischer Betreuer] Köhn, and Matthias [Akademischer Betreuer] Eder. "Heterobivalente Radiopharmaka um die intratumorale Heterogenität zu adressieren." Freiburg : Universität, 2021. http://d-nb.info/1238016650/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Röhrich, Anika. "Synthese und Charakterisierung Cyclam-basierter Multimere als Basis für Radiopharmaka." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2009. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-22013.

Full text

Abstract:

Verbindungen mit einer Vielzahl von Oberflächeneinheiten (Multimere) sind im Hinblick auf eine nuklearmedizinische Anwendung von besonderem Interesse, da durch definierte Strukturmodifizierung das Bindungsverhalten an bestimmte Zielstrukturen, die Löslichkeit und damit die Bioverteilung und Pharmakokinetik beeinflusst werden können. Baut man eine Verbindung so auf, dass sich im Inneren ein metallbindendes Zentrum befindet, ergibt sich einerseits die Möglichkeit, das Radiometall chemisch stabil zu binden, andererseits durch genannte Oberflächenfunktionalisierung eine spezifische Bindung im Zielgewebe zu erreichen. Im Rahmen dieser Arbeit wurden neuartige mehrfunktionale Verbindungen mit einer Cyclam-Kerneinheit synthetisiert. Cyclam bildet mit Cu(II)-Ionen äußerst stabile Komplexe, was im Hinblick auf eine radiopharmazeutische Anwendung der Radiometallkomplexe von 64Cu oder 67Cu für diagnostische und therapeutische Zwecke äußerst interessant ist. Für eine symmetrische Mehrfachfunktionalisierung wurde auf ein Tetraamin mit Cyclamkern zurückgegriffen. Die Kupplung von vier Dansylchlorid-Einheiten war erfolgreich. Über geschützte Glucosyl-Isothiocyanate wurden Derivate mit vier Zuckereinheiten gewonnen. Nach der Entfernung der Schutzgruppen wurde die Bindung an das kohlenhydratbindende Lektin Concanavalin A mittels isothermer Kalorimetrie bestimmt. Es war ein deutlicher Anstieg der Stabilitätskonstante K im Vergleich zu den monomeren Zuckern zu beobachten. Die Kinetik der Cu(II)-Komplexierung wurde UV/Vis-spektroskopisch bestimmt. Wegen der langsamen Cu-Komplexierungskinetik der Thioharnstoff-verbrückten Glycodendrimere wurde der Schwerpunkt bei den nachfolgenden Untersuchungen zur Kupplung von Peptiden über Amidbindungen gelegt. Nach zahlreichen erfolglosen Kupplungsversuchen von Peptiden mit einer freien Aminogruppe an Cyclamtetrapropionsäure im organischen Medium wurden im wässrigen Milieu Cyclamderivate mit ein bis zu drei Peptideinheiten durch Peptidkupplung erzeugt. Die Synthese kupplungsfähiger Peptidisothiocyanate blieb erfolglos. Schließlich führte eine Michael-Addition von Acrylamid-Arg-Tyr-OH und Acrylamid-Neurotensin(8-13)-OH an Cyclam zu den gewünschten tetrameren Verbindungen. Das Neurotensintetramer mit vier zielsuchenden Einheiten wurde für weiterführende radiochemische und radiopharmakologische Untersuchungen eingesetzt. Es kann unter milden Bedingungen sehr effizient mit 64Cu radiomarkiert werden, wobei eine spezifische Aktivität von 12 GBq pro µmol und Markierungsausbeuten von durchschnittlich 95-98% erzielt werden können. Erwartungsgemäß werden die Neurotensineinheiten unter diesen Bedingungen abgebaut, wobei im Vergleich zu freiem H-Neurotensin(8-13)-OH, welches innerhalb von zwei Minuten abgebaut wird, die In-vivo-Halbwertszeit des Tetramers 34 Minuten beträgt. Es konnte keine Transmetallierung beziehungsweise Transchelatisierung beobachtet werden, was die Stabilität des Komplexes zeigt. PET-Untersuchungen nach Applikation des 64Cu-markierten Neurotensin-Tetramers wiesen eine erhöhte Anreicherung von radioaktiver Substanz in Tumoren von LoVo- und HT29-Mäusen nach. Um zu unsymmetrischen Cyclamderivaten mit dem Ziel der gleichzeitigen Einführung zielsuchender, löslichkeitsvermittelnder und fluoreszierender Einheiten zu gelangen, wurden unterschiedliche Schutzgruppen eingesetzt. Die Blockierung primärer Aminogruppen eines Cyclam-Derivates mit MMTr-, Boc- und Z-Schutzgruppen lieferte Produkte, die sauber isoliert, aber nicht selektiv entschützt werden konnten. Daher wurden die Aminstickstoffatome des Cyclams direkt geschützt. Ausgehend von Cyclam-Boc3 konnten über Kupplungsreaktionen Aminosäure- und Dipeptidmethylester als unsymmetrische Cyclamderivate gewonnen werden. Damit ist ein Syntheseweg entwickelt worden, der die Darstellung unsymmetrischer Cyclamderivate mit einer definierten Anzahl von gewünschten biologisch aktiven Molekülen beziehungsweise löslichkeitsvermittelnder oder fluoreszierender Einheiten gestattet.

APA, Harvard, Vancouver, ISO, and other styles

4

Kienzle, Gabriele J. "Elektrochemische 18F-Fluorierung als neuer Ansatz zur Synthese aromatischer PET-Radiopharmaka." [S.l.] : [s.n.], 2002. http://deposit.ddb.de/cgi-bin/dokserv?idn=964959356.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kienzle, Gabriele J. "Elektrochemische 18 F-Fluorierung als neuer Ansatz zur Synthese aromatischer PET-Radiopharmaka." [S.l. : s.n.], 2002. http://www.bsz-bw.de/cgi-bin/xvms.cgi?SWB10236355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Michler, Christina. "Evaluierung von Radiopharmaka zur bildgebenden Darstellung der Pharmakoresistenz in einem Status epilepticus-Modell." Diss., lmu, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-154628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Burchardt, Carsten [Verfasser]. "Synthese, 68Ga-Markierung, Aufreinigung und Evaluierung von divalenten DO2A-basierenden Radiopharmaka / Carsten Burchardt." Mainz : Universitätsbibliothek Mainz, 2017. http://d-nb.info/1139509454/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Busse, Stefan. "Produktion, radiochemische Abtrennung und koordinative Kopplung von 90Nb zur Synthese potentieller Radiopharmaka für die Positronenemissionstomographie." [S.l.] : [s.n.], 2000. http://ArchiMeD.uni-mainz.de/pub/2000/0037/diss.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Weßmann, Sarah Hedwig [Verfasser]. "Neue und verbesserte Verfahren zur vereinfachten Herstellung von 18F-PET-Radiopharmaka in mikrofluidischen Systemen / Sarah Hedwig Weßmann." München : Verlag Dr. Hut, 2012. http://d-nb.info/102107280X/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Michler, Christina [Verfasser], and Heidrun [Akademischer Betreuer] Potschka. "Evaluierung von Radiopharmaka zur bildgebenden Darstellung der Pharmakoresistenz in einem Status epilepticus-Modell / Christina Michler. Betreuer: Heidrun Potschka." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2013. http://d-nb.info/1032862327/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Hiltner, Oliver [Verfasser], Wolfgang A. [Akademischer Betreuer] Herrmann, and Bernhard [Akademischer Betreuer] Rieger. "Faciale Rhenium(I)-NHC-carbonyl-Komplexe als potentielle Ausgangsverbindungen für Radiopharmaka / Oliver Hiltner. Gutachter: Bernhard Rieger. Betreuer: Wolfgang A. Herrmann." München : Universitätsbibliothek der TU München, 2012. http://d-nb.info/1030099642/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Blum, Till. "Development of no-carrier-added radioselenation methods for the preparation of radiopharmaceuticals." [S.l. : s.n.], 2003. http://deposit.ddb.de/cgi-bin/dokserv?idn=967330394.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Solbach, Christoph. "[11C]-Diazomethan : Entwicklung eines Herstellungsverfahrens und Anwendung zur 11C-Markierung von Pharmaka für die Positronen-Emissions-Tomographie /." [S.l.] : [s.n.], 2002. http://www.gbv.de/dms/bs/toc/35721868X.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Steinbach, Jörg, and Sepp Seifert. "Annual Report 2005 - Institute of Radiopharmacy." Forschungszentrum Dresden, 2010. http://nbn-resolving.de/urn:nbn:de:bsz:d120-qucosa-28449.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Steinbach, Jörg, and Sepp Seifert. "Annual Report 2005 - Institute of Radiopharmacy." Forschungszentrum Rossendorf, 2006. https://hzdr.qucosa.de/id/qucosa%3A21671.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Qatyana, Sizipiwe Misa. "Quality assurance of radiopharmacy in selected Gauteng Academic Hospitals." Thesis, University of Limpopo (Medunsa Campus), 2010. http://hdl.handle.net/10386/458.

Full text

Abstract:

Thesis (MSc(Med)(Pharmacy))University of Limpopo (Medunsa Campus), 2010
Introduction: The aim of this study was to identify and assess compliance with published radiopharmacy procedures in the radiopharmacy units in the Departments of Nuclear Medicine at Steve Biko Academic Hospital, Pretoria and Dr. George Mukhari Hospital, Ga-rankuwa. Objectives: To identify current written SOPs in use by the selected hospitals and to compare them with the two selected audit documents. To describe the Operational Levels (OLs) according to the IAEA classification, staffing and workload of the selected radiopharmacy units. To assess the two selected radiopharmacy units for compliance with the South African Department of Radiation Control audit criteria and the International Atomic Energy Agency Operational Guidance on Hospital Radiopharmacy (IAEA IOG). To obtain the views of staff at operational, clinical and managerial level regarding constraints in the work situation and the potential implementation of „best practice‟ approaches. To identify the elements from the IAEA IOG (IAEA 2008), which are realistically achievable in the South African hospital setting. To compile a comparative report of the assessment and to make recommendations for practice improvement. Method: Quality assurance audit documents (local and international) for “Hot” Laboratories were sourced and compared. Only three radiopharmacy audit documents could be sourced (namely the South African Department of Radiation Control (DOH, 2007), the International Atomic Energy Agency, Operational Guidance on Hospital Radiopharmacy (IAEA, 2008) and United Kingdom Radiopharmacy Group, Radiopharmacy audit (United Kingdom, 2006). The most stringent of these documents the IAEA IOG was selected and was used to assess the equipment, facilities, practices and work flow in the selected radiopharmacy units. A pilot study was conducted at the Nuclear Medicine Department in Tygerberg Hospital to get a clear understanding of the IOG audit document and to develop a system with which to approach the audit of the two study sites. The numbers and qualifications of staff involved in preparation of radiopharmaceuticals were documented as part of the audit. The IOG audit was conducted in the Nuclear Medicine Departments of the two Gauteng Academic Hospitals. Key informants who included radiopharmacists with international experience, currently working in South Africa and the HODs of the Nuclear Medicine Departments audited. The IOG audit results together with the FGD and Key informant information were used to compile recommendations. Results: For anonymity, the hospitals are referred to as hospital X and Y in the results. In both hospitals the chief radiographer is responsible for the radiopharmacy unit. In Hospital X xiii this responsibility is shared with the medical physicist. The radiographers that work in both hospitals have had specific “hot” laboratory training. Neither hospital has a formal system of radiopharmaceutical record keeping, nor do they compile or review their SOPs in any formal or regular way. Neither hospital performs an annual performance review to check the competencies of their staff. Hospital X has equipment that was not in use at the time the research was conducted. Both hospitals are authorised to handle certain radionuclides and radiopharmaceuticals/kits. Hospital Y offers a wider range of Nuclear Medicine services as compared to Hospital X. Hospital Y had already conducted the IAEA Nuclear Medicine IOG Hospital Radiopharmacy audit on their facility, whereas Hospital X had not. Hospital Y, when assessed on verifiable items, met 70 to 100% the required standards for class A items for all components apart from staff at OL2, dispensing protocols and waste management. Hospital X met 70 to 100% of standards only for staff at OL1, facilities and purchasing. In the components of staff at OL2, dispensing, preparation, quality assurance and waste management, the percentages of items where standards were met were much lower at only 12.5 to 55%. In terms of the ease of administration of the IAEA IOG audit, the researcher found that some of the audit items (references) were difficult to interpret because they were presented as multiple questions, some were duplicated, and some lacked clarity. Conclusion: It can be concluded from the results that the one shortfall that both hospitals share is in terms of documentation and record keeping. Both the hospitals‟ waste management procedures need to be documented. Neither hospital has a radiopharmacists in charge of the radiopharmacy unit. Recommendations: Recommendations are made in terms of staff training, facility upgrades and the introduction of formal standard operating procedures (SOPs) and log books for batch traceability in both Hospitals. Radiopharmacist involvement is recommended. Since there are not enough trained radiopharmacists in South Africa, it could be a part-time function of those qualified or they could share responsibility for more than one radiopharmacy. The audit questions could be revised in order to eliminate factors that were noted by the researcher such as multiple questions, duplication and ambiguity. The IAEA is commended for its role in the promotion of Nuclear Medicine and Radiopharmacy training and audits. Regional summaries of audit results should be available from the IAEA to aid comparative benchmarking and monitoring of progress over time.

APA, Harvard, Vancouver, ISO, and other styles

17

Niese, Siegfried. "Verflechtung von Wissenschaft und Produktion im Zentralinstitut für Kernforschung Rossendorf (1958 bis 1991)." Gesellschaft Deutscher Chemiker, 2012. https://slub.qucosa.de/id/qucosa%3A2833.

Full text

Abstract:

Die Produktion von Radiopharmaka im Zentralinstitut für Kernforschung Rossendorf (ZfK) von 1958-1991 ist ein Beispiel für eine enge Kooperation von interdisziplinärer Forschung und Produktion mit hervorragenden Möglichkeiten für den Austausch von Personal und Erfahrungen. Für das kurzlebige 99Tc, das zu ungefähr 90% in der nuklearmedizinischen Diagnostik eingesetzt wird, erfolgte der gesamte Prozess von der Bestrahlung von angereichertem U, chemischer Abtrennung des langlebigen Mutternuklids 99Mo bis zur Herstellung von Tc-Gerneratoren im Institut. Das ZfK gehörte weltweit zu den wichtigsten Produzenten von Radiopharmaka. Im Jahr 1972 wurde von der Regierung die Überführung der Produktion aus dem Institut in einen pharmazeutischen Betrieb zur Diskussion gestellt, aber aus wirtschaftlichen Gründen nicht durchgeführt.
The production of radio pharmaceuticals in the Nuclear Research Center Rossendorf (NRCR) from 1958 to 1991 is an example for a close cooperation of interdisciplinary research and fabrication with outstanding possibilities for the exchange of personal and experiences. For the short lived 99mTc, which is used in about 90% of the diagnosis in nuclear medicine, the whole process from irradiation of enriched U, chemical isolation of the longer lived mother nuclide 99Mo and the production of the Tc-generators were done in the institute. The NRCR was one of the most important producers of radio pharmaceuticals worldwide until 1991. In 1972 the government considered transforming of the fabrication from the institute to a pharmaceutical enterprise, but it has been not realized for economic reasons.

APA, Harvard, Vancouver, ISO, and other styles

18

Niese, Siegfried. "Verflechtung von Wissenschaft und Produktion im Zentralinstitut für Kernforschung Rossendorf (1958 bis 1991)." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2013. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-104579.

Full text

Abstract:

Die Produktion von Radiopharmaka im Zentralinstitut für Kernforschung Rossendorf (ZfK) von 1958-1991 ist ein Beispiel für eine enge Kooperation von interdisziplinärer Forschung und Produktion mit hervorragenden Möglichkeiten für den Austausch von Personal und Erfahrungen. Für das kurzlebige 99Tc, das zu ungefähr 90% in der nuklearmedizinischen Diagnostik eingesetzt wird, erfolgte der gesamte Prozess von der Bestrahlung von angereichertem U, chemischer Abtrennung des langlebigen Mutternuklids 99Mo bis zur Herstellung von Tc-Gerneratoren im Institut. Das ZfK gehörte weltweit zu den wichtigsten Produzenten von Radiopharmaka. Im Jahr 1972 wurde von der Regierung die Überführung der Produktion aus dem Institut in einen pharmazeutischen Betrieb zur Diskussion gestellt, aber aus wirtschaftlichen Gründen nicht durchgeführt
The production of radio pharmaceuticals in the Nuclear Research Center Rossendorf (NRCR) from 1958 to 1991 is an example for a close cooperation of interdisciplinary research and fabrication with outstanding possibilities for the exchange of personal and experiences. For the short lived 99mTc, which is used in about 90% of the diagnosis in nuclear medicine, the whole process from irradiation of enriched U, chemical isolation of the longer lived mother nuclide 99Mo and the production of the Tc-generators were done in the institute. The NRCR was one of the most important producers of radio pharmaceuticals worldwide until 1991. In 1972 the government considered transforming of the fabrication from the institute to a pharmaceutical enterprise, but it has been not realized for economic reasons

APA, Harvard, Vancouver, ISO, and other styles

19

Qatyana, Misa Sizipiwe. "Quality assurance of radiopharmacy in selected Gauteng Academic Hospitals." Thesis, University of Limpopo (Medunsa Campus), 2010. http://hdl.handle.net/10386/534.

Full text

Abstract:

Thesis (MSc (Med)(Pharmacy)) -- University of Limpopo (Medunsa Campus), 2010.
Introduction: The aim of this study was to identify and assess compliance with published radiopharmacy procedures in the radiopharmacy units in the Departments of Nuclear Medicine at Steve Biko Academic Hospital, Pretoria and Dr. George Mukhari Hospital, Ga-rankuwa. Objectives: To identify current written SOPs in use by the selected hospitals and to compare them with the two selected audit documents. To describe the Operational Levels (OLs) according to the IAEA classification, staffing and workload of the selected radiopharmacy units. To assess the two selected radiopharmacy units for compliance with the South African Department of Radiation Control audit criteria and the International Atomic Energy Agency Operational Guidance on Hospital Radiopharmacy (IAEA IOG). To obtain the views of staff at operational, clinical and managerial level regarding constraints in the work situation and the potential implementation of „best practice‟ approaches. To identify the elements from the IAEA IOG (IAEA 2008), which are realistically achievable in the South African hospital setting. To compile a comparative report of the assessment and to make recommendations for practice improvement. Method: Quality assurance audit documents (local and international) for “Hot” Laboratories were sourced and compared. Only three radiopharmacy audit documents could be sourced (namely the South African Department of Radiation Control (DOH, 2007), the International Atomic Energy Agency, Operational Guidance on Hospital Radiopharmacy (IAEA, 2008) and United Kingdom Radiopharmacy Group, Radiopharmacy audit (United Kingdom, 2006). The most stringent of these documents the IAEA IOG was selected and was used to assess the equipment, facilities, practices and work flow in the selected radiopharmacy units. A pilot study was conducted at the Nuclear Medicine Department in Tygerberg Hospital to get a clear understanding of the IOG audit document and to develop a system with which to approach the audit of the two study sites. The numbers and qualifications of staff involved in preparation of radiopharmaceuticals were documented as part of the audit. The IOG audit was conducted in the Nuclear Medicine Departments of the two Gauteng Academic Hospitals. Key informants who included radiopharmacists with international experience, currently working in South Africa and the HODs of the Nuclear Medicine Departments audited. The IOG audit results together with the FGD and Key informant information were used to compile recommendations. Results: For anonymity, the hospitals are referred to as hospital X and Y in the results. In both hospitals the chief radiographer is responsible for the radiopharmacy unit. In Hospital X xiii this responsibility is shared with the medical physicist. The radiographers that work in both hospitals have had specific “hot” laboratory training. Neither hospital has a formal system of radiopharmaceutical record keeping, nor do they compile or review their SOPs in any formal or regular way. Neither hospital performs an annual performance review to check the competencies of their staff. Hospital X has equipment that was not in use at the time the research was conducted. Both hospitals are authorised to handle certain radionuclides and radiopharmaceuticals/kits. Hospital Y offers a wider range of Nuclear Medicine services as compared to Hospital X. Hospital Y had already conducted the IAEA Nuclear Medicine IOG Hospital Radiopharmacy audit on their facility, whereas Hospital X had not. Hospital Y, when assessed on verifiable items, met 70 to 100% the required standards for class A items for all components apart from staff at OL2, dispensing protocols and waste management. Hospital X met 70 to 100% of standards only for staff at OL1, facilities and purchasing. In the components of staff at OL2, dispensing, preparation, quality assurance and waste management, the percentages of items where standards were met were much lower at only 12.5 to 55%. In terms of the ease of administration of the IAEA IOG audit, the researcher found that some of the audit items (references) were difficult to interpret because they were presented as multiple questions, some were duplicated, and some lacked clarity. Conclusion: It can be concluded from the results that the one shortfall that both hospitals share is in terms of documentation and record keeping. Both the hospitals‟ waste management procedures need to be documented. Neither hospital has a radiopharmacists in charge of the radiopharmacy unit. Recommendations: Recommendations are made in terms of staff training, facility upgrades and the introduction of formal standard operating procedures (SOPs) and log books for batch traceability in both Hospitals. Radiopharmacist involvement is recommended. Since there are not enough trained radiopharmacists in South Africa, it could be a part-time function of those qualified or they could share responsibility for more than one radiopharmacy. The audit questions could be revised in order to eliminate factors that were noted by the researcher such as multiple questions, duplication and ambiguity. The IAEA is commended for its role in the promotion of Nuclear Medicine and Radiopharmacy training and audits. Regional summaries of audit results should be available from the IAEA to aid comparative benchmarking and monitoring of progress over time.

APA, Harvard, Vancouver, ISO, and other styles

20

Carvalho, Juliane de Sá, and Instituto de Engenharia Nuclear. "Unificação de parâmetros de proteção radiológica para programas de treinamento de profissionais de radiofarmácia hospitalar." Instituto de Engenharia Nuclear, 2018. http://carpedien.ien.gov.br:8080/handle/ien/2651.

Full text

Abstract:

Submitted by Almir Azevedo (barbio1313@gmail.com) on 2018-08-13T12:30:08Z No. of bitstreams: 1 dissertação mestrado ien 2018 Juliane de Sá Carvalho.pdf: 773861 bytes, checksum: 2659032c499066d29bd53a810450aa21 (MD5)
Made available in DSpace on 2018-08-13T12:30:08Z (GMT). No. of bitstreams: 1 dissertação mestrado ien 2018 Juliane de Sá Carvalho.pdf: 773861 bytes, checksum: 2659032c499066d29bd53a810450aa21 (MD5) Previous issue date: 2018-06
A Farmácia nuclear ou radiofarmácia de um serviço de medicina nuclear é o setor responsável, entre outras atividades, pelo preparo e dispensação dos radiofármacos. Para que a prática dos indivíduos ocupacionalmente expostos neste ambiente aconteça em condições seguras, devem ser seguidos requisitos básicos de proteção radiológica e devem ser garantidas ações para a qualificação e treinamento destes profissionais, visando o aprimoramento e compreensão dos aspectos de radioproteção em suas respectivas funções. Requisitos de radioproteção são dispostos pelas normas da CNEN, pelas regulamentações da ANVISA e por recomendações internacionais de organizações relevantes ligadas à proteção radiológica. A experiência e situações específicas da rotina dos profissionais também agregam informações a respeito dos cuidados a serem tomados na manipulação de radionuclídeos. Logo, há uma profusão de informação em diferentes fontes sobre os aspectos que devem ser levados em consideração em treinamentos. Diante disto, este trabalho objetiva unificar os requisitos de segurança e proteção radiológica, referentes à infraestrutura e atividades da radiofarmácia de um serviço de medicina nuclear, com vistas a subsidiar treinamentos de indivíduos ocupacionalmente expostos nesses ambientes. Para isto, foi realizada a análise de recomendações, normas e regulamentações específicas para radiofarmácia, e foi realizado o acompanhamento in loco dos procedimentos. Acredita-se que os parâmetros obtidos na unificação poderão servir de plataforma para treinamento dos profissionais da radiofarmácia de serviços de medicina nuclear.
The nuclear pharmacy or radiopharmacy from a nuclear medicine service is the sector responsible, among other activities, for preparation and dispensing of radiopharmaceuticals. For the practice of occupationally exposed individuals in this environment occurs under safe conditions, basic requirements for radiation protection must be followed and actions must be guaranteed for the qualification and training of these professionals aiming at improving and understanding aspects of radioprotection in their respective functions. Radioprotection requirements are established by CNEN norms, ANVISA regulations and international recommendations of relevant organizations related to radiation protection. The routine situations of professionals also aggregate information regarding the care to be taken in dealing with radionuclides. Therefore, there is a plenty of information on aspects that should be taken into account in training. In view of this, the work aims to unify the requirements of safety and radiological protection, referring to the infrastructure and activities of the radiopharmacy of a nuclear medicine service, as a subsidy for the training of occupationally exposed individuals in these environments. For this, the analysis of recommendations, norms and regulations, specific for radiopharmacy was realized, and on-site monitoring of radiopharmaceuticals was performed. It is believed that the parameters obtained in the unification may serve as a training platform for radiopharmacy professionals of nuclear medicine services.

APA, Harvard, Vancouver, ISO, and other styles

21

Costa, Renata Ferreira. "Desenvolvimento de métodos e preparação de microesferas de polímero e resinas marcadas com Hólmio-166." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-21092011-102343/.

Full text

Abstract:

A expansão do desenvolvimento de radionuclídeos para uso em terapia de tumores, permite que técnicas de tratamento de tumores sejam mais seletivas e adequadas. Novos agentes têm como finalidade reduzir o tempo de tratamento e acelerar o tempo de recuperação de muitos pacientes. O principal objetivo deste trabalho é o desenvolvimento de microesferas de ácido lático e resina marcadas com Hólmio-166, para que se obtenha um radiofármaco que possa oferecer um tratamento localizado do tumor e, portanto para que se tenha a máxima irradiação do tumor e a diminuição dos efeitos de toxicidade nos tecidos adjacentes saudáveis. A metástase hepática é a principal causa de morte de pacientes com câncer de colo retal, para estes pacientes a resposta da quimioterapia e da radioterapia é baixa. Uma alternativa é a radioterapia interna seletiva utilizando microesferas marcadas com Hólmio-166, um emissor b (Emax=1,84 MeV), com um alcance máximo no tecido de 8,4mm e emissor de fótons (81 keV, 6,2%), apropriado para a aquisição de imagens. A produção de Hólmio-166 é possível no reator nuclear IEA-R1 (IPEN-CNEN/SP), um reator de pesquisa com baixo fluxo de nêutrons. O Hólmio tem uma abundância de 100% na natureza e seção de choque de 64 barns. Isso permite produzir uma atividade de 344mCi (~12GBq) (reator IEA-R1, 60 horas, 4,0x 1013n .s-1.cm-2), o suficiente para produção de doses terapêuticas. As resinas de troca catiônica, AG50W-X2, AG50W-X8, Amberlite, Sephadex e Sepharose, foram marcadas com 166Ho. Todas elas apresentaram um ótimo resultado de marcação. As resinas AG50W-X2, AG50W-X8, Amberlite e Sephadex não têm o tamanho de partícula ideal para terapia de tumores hepáticos, porém foi proposto que partículas com tamanho entre 100-450 m podem ser usadas no tratamento de tumores de cabeça e pescoço. A resina Sepharose tem as características essenciais para terapia de tumores hepáticos. Entretanto, estudos in vivo devem ser realizados para comprovar a sua eficácia. O preparo das microesferas de ácido lático não foi bem sucedido, mas a primeira fase da preparação apresentou bons resultados.
A surge in research activity is expanding the applications for therapeutic radiopharmaceuticals, which are employing more sophisticated targeting methodologies and more appropriate therapeutic isotopes for the tumors being treated. These new agents will reduce treatment time and accelerate recovery for many patients. The aim of this work is the development of resin-based and acid lacticbased microspheres labeled with 166Ho, in order to obtain selective delivery of radioisotopes to the tumor, thus maximizing the irradiation effect while sparing toxicity to the surrounding healthy liver. Liver metastases cause the majority of deaths from colorectal cancer, and response to chemotherapy and external radiotheraphy is poor. An alternative is an internal radionuclide therapy using microspheres labeled with 166Ho, a beta minus emitter (Emax=1.84 MeV), with maximum tissue range 8.4 mm, that also emits photons (81keV, 6.2%) suitable for imaging. The production of 166Ho is feasible in the IEA-R1 Reactor at IPEN-CNEN/SP, a low power reactor with low neutron fluxes. The nuclear reaction has a cross section of 64 barns and 165Ho has a natural abundance of 100%. It is possible to produce 344 mCi (~12GBq) (IEA-R1 Reactor, 60 hours, 4,0x 1013n .s-1.cm-2) a sufficient therapeutic dose, depending on the demand of doses. The cation exchange resins, AG50W-X2, AG50W-X8, Amberlite, Sephadex and Sepharose, were labeled with 166Ho. All the resins showed a very good retention. Although AG50W-X2, AG50W-X8, Amberlite and Sephadex did not have the right particle size, it is suggested that particles of 100-450 m could be used in the treatment of head-and-neck tumours. Sepharose labeled with 166Ho has essential characteristics for treatment liver therapy. However, further in vivo studies should be performed to prove its effectiveness. The preparation of acid lactic-based microspheres was not successful, but the first step of the preparation was very effective.

APA, Harvard, Vancouver, ISO, and other styles

22

Wentling, II William A. II. "Economic Effects on Radiopharmacy Systems| The Impact of the Nuclear Regulatory Commission's Proposed Radiation Exposure Limits." Thesis, Robert Morris University, 2014. http://pqdtopen.proquest.com/#viewpdf?dispub=3629877.

Full text

Abstract:

In the spring of 2012, based on recommendations from the International Commission on Radiological Protection (ICRP), the Nuclear Regulatory Commission (NRC) proposed three amendments to reduce current radiation exposure limits for radiation workers. The NRC proposals have caused some concern within the radiopharmaceutical industry. The regulatory changes may affect the ability of radiopharmacy workers to remain on the job, thereby inflicting additional costs to radiopharmacies if they are required to replace workers who have reached their yearly exposure limits.

This research sought to determine whether or not the new regulatory proposals will in fact have a financial impact on the radiopharmaceutical industry. This research was a retrospective case study that analyzed four radiopharmaceutical production facilities and their employee radiation exposure reports. Results of the study suggest that the NRC's proposed amendments to reduce radiation levels will not have a great adverse effect, either financially or from an employee exposure standpoint, on the current radiopharmacy system. The research demonstrated that existing as low as reasonably achievable (ALARA) standards have resulted in radiopharmacy workers receiving exposures well below the current limits, and within the NRC proposed limits. Of 77 employees studied over a 10 year period, only seven employees (9 %) would have been removed from the production process for overexposure to any one of the NRC's proposed limits. However, this research reviewed small a subset of four radiopharmacies and did not examine other industries and professions utilizing ionizing radiation.

APA, Harvard, Vancouver, ISO, and other styles

23

Catanoso, Marcela Forli. "Purificação de 123I e 131I para marcação de biomoléculas." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-15092011-144958/.

Full text

Abstract:

O 123I e 131I são dois radioisótopos de iodo amplamente utilizados em medicina nuclear. O 123I é utilizado para diagnóstico através da técnica de SPECT e produzido no IPEN em cíclotron a partir da reação 124Xe (p,2n)123Cs->123Xe-> 123I. Já o 131I pode ser utilizado tanto para o diagnóstico quanto para o tratamento devido às suas características físicas de decaimento β- e sua elevada emissão de raios-γ. Sua produção no IPEN é realizada utilizando um reator nuclear a partir da reação indireta: 130Te(n, γ)->131Te->131I, onde são irradiados alvos contendo Te. Os radiofármacos preparados com estes radioisótopos passam por um rigoroso controle de qualidade onde a pureza química dos radioisótopos primários 123I e 131I está dentro dos limites estabelecidos atualmente. Entretanto, a presença de alguns contaminantes químicos prejudica a marcação de biomoléculas (anticorpos monoclonais e peptídeos) que produziriam radiofármacos de primeira geração para a área de oncologia. Com isso, o objetivo deste trabalho consiste na obtenção de um método de purificação dos radionuclídeos 123I e 131I para uma maior eficiência na marcação de biomoléculas, estabelecendo também controle do processo nos métodos de produção destes radioisótopos. A metodologia foi dividida em 3 etapas: Determinação da pureza radionuclídica através da análise de amostras de 123I e 131I no detector de germânio-hiperpuro (HPGe), determinação da pureza química de 123I e 131I através da técnica de ICP-OES e análise do comportamento de 131I em diversos adsorvedores para posterior utilização dos adsorvedores mais adequados para os testes de purificação, analisando o comportamento dos possíveis contaminantes. Quanto a pureza radionuclídica, pode-se observar a presença de radionuclídeos de Te e Co nas amostras de 131I e radionuclídeos de Te, Tc e Co para 123I. A análise de pureza química determinou a presença principalmente de Al e Mo nas amostras de 123I, provenientes do material do porta-alvo e da janela do porta-alvo e Al e Te nas amostras de 131I, provenientes da cápsula de Al utilizada na irradiação e do alvo, respectivamente. O estudo de retenção e eluição de 131I selecionou os meios adsorvedores mais promissores para sua purificação, no caso a resina catiônica Dowex 50WX4 que apresentou excelente eluição de 131I e retenção das impurezas radionuclídicas presentes em sua solução.
The 123I and 131I are iodine radioisotopes widely used in Nuclear Medicine. The radioisotope 123I is used in diagnosis through the SPECT technique and is routinely produced at IPEN in cyclotron through the reaction: 124Xe (p, 2n) 123Cs -> 123Xe -> 123I. The radioisotope 131I is used both in diagnosis and therapy due to its physical characteristics of decay by β- and its γ-ray emissions that are softened with the use of specific collimators for diagnosis. It is routinely produced at IPEN using the nuclear reactor through the indirect reaction: 130Te (n, γ) ->131Te -> 131I, irradiating compounds containing Te. The radiopharmaceuticals prepared with these radioisotopes go through rigorous quality control tests and the chemical purity of the primary radioisotopes 123I and 131I are within the permissible limits currently defined. However, the presence of some chemical contaminants can prejudice the biomolecules labeling (monoclonal antibodies and peptides), that will produce radiopharmaceuticals of first generation to the oncology area. The aim of this work was to obtain a new purification method of these radioisotopes, allowing the labeling of biomolecules and also to established a process control on those radioisotopes. The methodology was separated on 3 steps: Evaluation of 123I e 131I radionuclidic purity using a hiperpure germanium detector, chemical purity using ICP-OES and the retention and elution study of 131I in several absorbers to choose the most appropriate for the purification tests analyzing the behavior of the possible contaminants. The radionuclidic analyses showed the presence of Te and Co on 131I samples and Te, Tc e Co on 123I samples. The chemical purity analyses showed the presence of Al and Mo in 123I, coming from the window material of the target holder and the presence of Al and Te in 131I samples, coming from the target holder and the target, respectively. The retention and elution study selected the most promising adsorber to the purification technique, in this case, the Dowex 50WX4 cationic exchange that showed an excellent 131I elution and the retention of radionuclidic and chemical impurities present in the solution.

APA, Harvard, Vancouver, ISO, and other styles

24

Struthers, Harriet Sarah Rose. ""Click-to chelate" : an efficient strategy for the development of organometallic technetium and rhenium compounds for potential application in radiopharmacy /." [S.l.] : [s.n.], 2009. http://e-collection.ethbib.ethz.ch/show?type=diss&nr=18281.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Schibli, Roger Schibli Roger Schibli Roger. "Synthetic and structural considerations of organometallic compounds of the elements technetium and rhenium for use in radiopharmacy a habilitation thesis /." Zürich : ETH, Eidgenössische Technische Hochschule Zürich, Department of Chemistry and Applied Biosciences, 2003. http://e-collection.ethbib.ethz.ch/show?type=habil&nr=18.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Didio, Robert Joseph. "Uma nova metodologia para planejamento estratégico utilizando mapas tecnológicos e detecção de frentes emergentes de pesquisa aplicada à radiofarmácia." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-03082011-140659/.

Full text

Abstract:

Esta pesquisa desenvolveu uma nova metodologia para dar apóio ao planejamento estratégico, utilizando o processo de elaboração de mapas tecnológicos (TRM Technological Roadmaps), associado com a aplicação do processo de detecção de frentes emergentes de pesquisa em bases de dados de artigos científicos e de patentes. A inovação introduzida nesta pesquisa é a customização do processo de TRM à radiofarmácia e, especificamente, a sua associação à técnica de detecção de frentes emergentes de pesquisa, a fim de comprovar resultados e estabelecer uma nova metodologia muito útil ao planejamento estratégico desta área de negócios. A unidade de negócios DIRF Diretoria de Radiofarmácia do IPEN CNEN/SP foi utilizada como base do estudo e implementação desta metodologia apresentada neste trabalho.
This research aims the development of a new methodology to support the strategic planning, using the process of elaboration of technological maps (TRM - Technological Roadmaps), associated with application of the detection process of emerging fronts of research in databases of scientific publications and patents. The innovation introduced in this research is the customization of the process of TRM to the radiopharmacy and, specifically, its association to the technique of detection of emerging fronts of research, in order to prove results and to establish a new and very useful methodology to the strategic planning of this area of businesses. The business unit DIRF - Diretoria de Radiofarmácia - of IPEN CNEN/SP was used as base of the study and implementation of this methodology presented in this work.

APA, Harvard, Vancouver, ISO, and other styles

27

Barthel, Henryk [Verfasser]. "Implementierung der Kleintier-PET in die präklinische Evaluierung von [18F]Fluoretanidazol, einem neuen Radiopharmakon für die nuklearmedizinische Bildgebung von Tumorhypoxie / Henryk Barthel." Aachen : Shaker, 2011. http://d-nb.info/1098039424/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Costa, Renata Ferreira. "Desenvolvimento de métodos de purificação do Gálio-67 e Gálio-68 para a marcação de biomolécula." Universidade de São Paulo, 2012. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-29062012-141412/.

Full text

Abstract:

Há mais de 50 anos os geradores de 68Ge/68Ga vêm sendo desenvolvidos, obtendo o 68Ga sem a necessidade da instalação de um cíclotron próximo à radiofarmácia ou ao centro hospitalar que tenha um PET/CT. O 68Ga é um emissor de pósitron com baixa emissão de fóton (β+, 89%, 1077 keV) e meia vida de 67,7 minutos, compatível com a farmacocinética de moléculas de baixo peso molecular, como peptídeos e fragmentos de anticorpos. Além disso, a química do Ga permite a ligação estável com agentes quelantes acoplados com peptídeos, como o DOTA. Todas estas características do 68Ga aliado a tecnologia PET/CT permitiram avanços em imagem molecular, como no diagnóstico de doenças de origem neuroendócrina. Entretanto, o eluato de 68Ga proveniente dos geradores de 68Ge/68Ga comerciais, ainda contém altos níveis de contaminantes, como o 68Ge e outros metais que competem quimicamente com o 68Ga, como o Fe3+ e Zn2+ e, como consequência, há redução do rendimento de marcação com biomoléculas. Quanto menor a quantidade de impurezas no eluato, a competição entre o peptídeo radiomarcado e peptídeo não marcado será menor e a qualidade de imagem será melhor, por isso existe a necessidade de diminuir a quantidade destes metais. Portanto, os objetivos deste trabalho são avaliar os métodos de purificação do 68Ga para a marcação de biomoléculas, com ênfase no estudo das impurezas químicas presentes nos radioisótopos primários, e desenvolver um método de purificação inédito. Diversos métodos de purificação foram estudados. Na purificação em resina catiônica tradicional e comercial, em que o 68Ga é adsorvido em resina catiônica e eluído em uma solução de acetona/ácido, a resina utilizada não é disponível comercialmente. Várias resinas catiônicas foram testadas simulando o processo comercial, e o uso das menores partículas da resina catiônica AG50W-X4 (200-400 mesh) foi a que apresentou os melhores resultados. Um método inovador foi a cromatografia por extração, onde o éter diisopropílico é adsorvido em resina XAD 16 e o 68Ga eluído em água deionizada. Apesar dos resultados de recuperação do 68Ga e a separação entre o 68Ga e o 65Zn terem sido bons, não houve reprodutibilidade na purificação dos metais. O método mais promissor e inédito foi a purificação do 68Ga em resina catiônica em meio básico que apresentou bons resultados, principalmente em relação à redução do Zn (98 ± 2)%, o contaminante químico encontrado em maior abundância no eluato de 68Ga. A redução total de impurezas foi (95 ± 4)%. Os peptídeos DOTATOC/DOTATATO foram marcados com o 68Ga em três diferentes formas: purificado em meio básico, por extração por solventes e sem a purificação prévia, o melhor resultado de rendimento de marcação do 68Ga DOTATATO foi obtido após a purificação do 68Ga em meio básico, comprovando a eficiência do processo.
For more than fifty years, the long-lived 68Ge/68Ga generators have been in development, obtaining 68Ga without the need of having in house cyclotron, which is a considerable convenience for PET centers that have no nearby cyclotrons. 68Ga decays 89% by positron emission and low photon emission (1077 keV) and the physical half life of 67.7 minutes is compatible with the pharmacokinetics of low biomolecular weight substances like peptides and antibody fragments. Moreover, its established metallic chemistry allows it to be stably bound to the carrier peptide sequence via a suitable bifunctional chelator, such as DOTA. All these reasons together with the technology of PET/CT allowed advances in molecular imaging, in particular in the diagnosis of neuroendocrine diseases. However, the eluate from the commercial 68Ge/68Ga generators still contains high levels of long lived 68Ge, besides other metallic impurities, which competes with 68Ga with a consequent reduction of the labeling yield of biomolecules, such as Fe3+ and Zn2+. Thus, the lower the amount of impurities in the eluate, the competition between the radiolabeled and unlabeled peptide by the receptor will be smaller and the quality of imaging will be better, a subsequent purification step is needed after the generator elution. The aim of this work is to evaluate different purifications methods of 68Ga to label biomolecules, with emphasis on the study of the chemical impurities contained in the eluate and to develop a new purification method. Several purification methods were studied. Many cationic resin were tested simulating the commercial process. 68Ga is adsorbed in cationic resin, which is not commercial available and eluted in acid/acetone solution. The use of minor particles of cationic resin AG50W-X4 (200-400 mesh) showed the best results. An innovate method was the extraction chromatography, wich is based on the absorption of diisopropyl ether in XAD 16 and 68Ga recovery in deionized water. Although the results regarding to 68Ga recovery and the radiochemical separation between 68Ga and 65Zn were excellent, there was no reproducibility on the purification of metals. The most promising and innovative method was the 68Ga purification performed by cationic resin in basic media, which presented the best results, especially regarding the Zn reduction (98 ± 2)%, the chemical contaminant found in great abundance in 68Ga eluate. The total impurities reduction was (95 ± 4)%. The peptides DOTATOC/DOTATATE were labeled 68Ga in three different forms: purified 68Ga in basic solution, through solvent extraction and no purified 68Ga. The best result was achieved with DOTATATE labeling with purified 68Ga in basic media, proving the purification process efficiency.

APA, Harvard, Vancouver, ISO, and other styles

29

Kaiser, Franz R. [Verfasser], Rudolf [Akademischer Betreuer] Werner, Takahiro [Akademischer Betreuer] Higuchi, and Andreas K. [Gutachter] Buck. "Ein 18F markiertes PET-Radiopharmakon (LMI1195) zur Bildgebung des Norepinephrin-Stoffwechsels im Rattenherz / Franz R. Kaiser ; Gutachter: Andreas K. Buck ; Rudolf Werner, Takahiro Higuchi." Würzburg : Universität Würzburg, 2021. http://d-nb.info/1241965560/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Gupta, Antje. "In-vivo und In-vitro-Stabilität und Metabolismus von Gemischtligandkomplexen des 99m Tc." Doctoral thesis, Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2000. http://nbn-resolving.de/urn:nbn:de:swb:14-994673277281-08594.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Lafratta, Alyne Eloise. "Preparo e avaliação dos complexos de derivados de tiossemicarbazonas com(67/68 Ga) gálio, [99mTc] tecnécio e (111In)índio, como potenciais agentes para detecção de tumores." Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/5/5155/tde-22082016-153056/.

Full text

Abstract:

Nas últimas décadas a medicina nuclear tornou-se uma grande aliada no auxílio ao diagnóstico de doenças e também para o tratamento do câncer. Parte deste sucesso está relacionada à constante pesquisa e desenvolvimento de novos radiofármacos. Uma classe de molécula que vem se mostrando promissora para o tratamento de tumores, tanto na sua forma orgânica quanto na forma de complexos organo-metálicos, é a tiossemicarbazona e seus derivados, os quais também podem formar complexos com radioisótopos metálicos dando origem a radiofármacos para diagnóstico e terapia. Neste trabalho foram preparados complexos com o ligante benzil-5-hidroxi-3-metil-5-fenil-4,5-diidro-1H-pirazol-1-carboditionato (H2bdtc) com os radioisótopos [99mTc]tecnécio, (67/68Ga)gálio e (111In)índio, e foram avaliados a pureza radioquímica, Log P e a estabilidade na presença de L-cisteína, L-histidina, soro albumina humana (SAH) e plasma de sangue humano; também foram avaliadas a taxa de captação dos radiofármacos in vitro em células de melanoma murino B16F10 e TM1M, além da avaliação da captação ex vivo e in vivo utilizando camundongos C57B/6 inoculados com as duas linhagens tumorais. Com o [99mT]tecnécio foram obtidos dois complexos diferentes, dependendo da concentração do PBS na solução, sendo que em um deles foi possível confirmar sua estrutura como [[99mTc]O(bdtc)(Hbdtc)] a partir do complexo de rênio [ReO(bdtc)(Hbdtc)], o outro complexo de [99mTc]tecnécio, bem como de (67/68Ga)gálio e (111In)índio não tiveram a estrutura caracterizada. A eficiência de marcação dos complexos foi superior a 90 %, com Log P maior que 1 para os complexos [[99mTc]O(bdtc)(Hbdtc)], [[99mTc]-bdtc] e [67/68Ga-bdtc] e 0,9 para [111In-bdtc]. Todos os complexos se mostraram com boa estabilidade na presença de L-cisteína e L-histidina, principalmente na primeira hora de incubação, mas não o foram na presença de SAH e plasma. A captação in vitro dos complexos em células B16F10 e TM1M variou entre 0,6 % e 1,8 %, e nos estudos de biodistribuição ex vivo foi obesrvada intensa e persistente captação hepática e no baço, superando 90 %, e captação no tumor variando de 0,2 % a 3 %, enquanto que nas imagens in vivo não foi possível observar de forma uma adequada captação nos tumores a ponto de permitir o uso como agente de diagnóstico. Os resultados permitem concluir que os complexos de derivados tiossemicarbazonas podem formar complexos com diferentes metais, mas novos derivados devem ser preparados para tentar melhorar o desempenho nos sistemas biológicos. Os experimentos com animais foram aprovados pela Comissão de Ética em Pesquisa da Faculdade de Medicina - USP, processo 372/12
In recent decades, nuclear medicine has been used as diagnostic agent for disease and for the treatment of cancer. Part of this success is related to the constant research and development of new radiopharmaceuticals. Thiosemicarbazone and their derivatives have proven to be promising agent for the treatment of tumors, both in its organic form or as organo-metallic complexes. Also, they can to form complexes with metal radioisotopes giving radiopharmaceuticals for diagnosis and therapy. In this work we prepared complex of benzyl-5-hydroxy-3-methyl-5-phenyl-4,5-dihydro-1H-pyrazol-1-carboditionato (H2bdtc) with radioisotopes [99mTc]technetium (67/68Ga)gallium and (111In)indium and the radiochemical purity, Log P and stability in the presence of L-cysteine, L-histidine, human serum albumin (HSA) and human blood plasma were assessed; also were assessed the in vitro uptake rate of radiopharmaceuticals in murine melanoma cells B16F10 and TM1M, besides the evaluation of ex vivo uptake and in vivo using C57Bl/6 mice inoculated with both tumor lines. With [99mT] technetium two different complexes were obtained, depending on the concentration of the PBS in the solution, and one of them was had its structure to confirm as [[99mTc]O(bdtc)(Hbdtc)] from the standard rhenium complex [ReO(bdtc)(Hbdtc)], the other [99mTc] echnetium complex as well as (67/68Ga)gallium and (111In)indium not have characterized the structure. The labeling efficiency of compleos was higher than 90%, with log P higher than 1 for the complexes [[99mTc]O(bdtc)(Hbdtc)], [[99mTc]-bdtc] and [(67/68Ga)-bdtc] and 0.9 to [111In-bdtc]. All the complexes showed good stability in the presence of L-cysteine and L-histidine, especially in the first hour of incubation, but not in the presence of HSA and plasma. The uptake in vitro complexes in B16F10 and TM1M cells varied between 0.6% and 1.8%, and in ex vivo biodistribution studies was obesrvada intense and persistent liver uptake and spleen, exceeding 90%, and tumor uptake in changing from 0.2% to 3%, while in vivo imaging was not possible to observe a properly uptake in tumors, not allowing to use these molecules as a diagnostic agent. The results indicate that the thiosemicarbazone derivative complex can give complexes with different metals, but new derivatives should be prepared to try to improve performance in biological systems. The animal experimentation was approved by Comissão de Ética em Pesquisa da Faculdade de Medicina - USP, proccess 372/12

APA, Harvard, Vancouver, ISO, and other styles

32

Röhrich, Anika [Verfasser]. "Synthese und Charakterisierung Cyclam-basierter Multimere als Basis für Radiopharmaka / von Anika Röhrich." 2009. http://d-nb.info/1007309059/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Adleff, Alexander-Klaus. "Synthese von funktionalisierten Rhenium-Schiffbase-Verbindungen zur Kopplung an Peptide als Bausteine für Radiopharmaka /." 2006. http://www.gbv.de/dms/bs/toc/511753187.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kienzle, Gabriele J. [Verfasser]. "Elektrochemische 18F-Fluorierung als neuer Ansatz zur Synthese aromatischer PET-Radiopharmaka / vorgelegt von Gabriele J. Kienzle." 2002. http://d-nb.info/964959356/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Busse, Stefan [Verfasser]. "Produktion, radiochemische Abtrennung und koordinative Kopplung von 90Nb zur Synthese potentieller Radiopharmaka für die Positronenemissionstomographie / Stefan Busse." 2000. http://d-nb.info/959886443/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Kaiser, Franz R. "Ein \(^{18}\)F markiertes PET-Radiopharmakon (LMI1195) zur Bildgebung des Norepinephrin-Stoffwechsels im Rattenherz." Doctoral thesis, 2021. https://doi.org/10.25972/OPUS-24433.

Full text

Abstract:

Der neuartige (18)F-markierte Tracer, LMI1195 (N-[3-bromo-4-(3-(18)F-fluoro-propoxy)-benzyl]-guanidine) wurde für die Bildgebung des sympathischen Nervensystems entwickelt; die hohe Spezifität dieses Tracers für den neuralen Uptake-1 Mechanismus wurde bereits gezeigt in Zell-Versuchen, sowie in Studien mit Kaninchen- und nicht menschlichen Primaten zur Bestimmung des kardialen Tracer-Uptakes. Das Ziel dieser Studie war es, die Mechanismen des kardialen (18)F-LMI1195-Uptakes in der Ratte zu untersuchen, von der bekannt ist, dass es neben dem Uptake-1 Mechanismus weitere Arten der Noradrenalin-Aufnahme im Herzen gibt
The novel PET Tracer N-[3-bromo-4-(3-18F-fluoropropoxy)-benzyl]-guanidin (LMI1195) has recently been developed for the imaging of the sympathetic nervous system. Previous studies in cell models, as well as rabbit and nonhuman primate studies have shown a high specificity for the cardiac neural uptake-1 mechanism. The aim of this study was to further assess the mechanisms of the cardiac 18-F-LMI1195 uptake in the rat heart, known to have additional, differing norepinephrine uptake mechanisms besides neural uptake-1

APA, Harvard, Vancouver, ISO, and other styles

37

Bauerfeind, Matthias [Verfasser]. "Darstellung von radioaktiv markiertem "Luteinising Hormone Releasing Hormone" als Radiopharmakon für die Radiodiagnostik und Tumortherapie sowie Untersuchungen zum Einsatz von Aktivestern zur Darstellung von DOTA-Peptid-Konjugaten / vorgelegt von Matthias Bauerfeind." 2006. http://d-nb.info/982576838/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic 'Radiopharmaka'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles